

MAY 10 2002

PATENT
76649002

ATTORNEY DOCKET NO. 047664-1002

TECH CENTER 1600/2900

MAY 13 2002

RECEIVED

Brita SCHULZE *et al.*

Group Art Unit: 1617

Examiner: L. Wells

For: CATIONIC DIAGNOSTIC, IMAGING AND
THERAPEUTIC AGENTS ASSOCIATED WITH
ACTIVATED VASCULAR SITES

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO-1449. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application.

Copies of the listed documents are attached. Applicants respectfully request that the Examiner consider the listed documents and evidence that consideration by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If it should be determined that any of the listed documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such document.


312

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. §1.136(a)(3).

Respectfully submitted,

MORGAN, LEWIS & BOCKIUS LLP


Sally P. Teng
Reg. No. 45,397

Dated: May 10, 2002
Customer No. 09629
MORGAN, LEWIS & BOCKIUS LLP
1111 Pennsylvania Avenue, NW
Washington, D.C. 20004
(202) 739-3000

INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) PTO Form 1449	Attorney Docket No. 047664-5002	Application No. 09/847,538
	<div style="display: inline-block; border: 1px solid black; padding: 5px;"> RECEIVED MAY 10 2002 </div>	
	Applicants: Brita Schulze <i>et al.</i>	Filing Date: 05/03/01

U.S. PATENT DOCUMENTS							
*Examiner Initial	Document Number	Date	Name	Class	Sub Class	Filing Date	
	5,322,678	06/21/94	Morgan, Jr. <i>et al.</i>	424	1.53	02/17/88	
	5,635,180	06/03/97	Morgan, Jr. <i>et al.</i>	424	183.1	09/26/95	
	5,990,179	11/23/99	Gyory <i>et al.</i>	514	970	04/28/95	
	5,990,286	11/23/99	Khawli <i>et al.</i>	530	387.1	01/10/97	
	5,837,283	11/17/98	McDonald <i>et al.</i>	424	450	03/12/97	

FOREIGN PATENT DOCUMENTS							
	Document Number	Date	Country	Class	Sub Class	Translation Yes No	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
✓	Folkman, 1990, Journal of the National Cancer Institute, 82(1): 4-6.
-	Kok <i>et al.</i> , 1998, Renal Failure, 20(2): 211-217.
-	McLean <i>et al.</i> , 1997, American Physiological Society, H387-H404.
✓	Taguchi <i>et al.</i> , 1998, Arch. Histol. Cytol., 61(3): 243-252.
-	Thurston <i>et al.</i> , 1998, J. Clin. Invest., 101(7): 1401-1413.
✓	Yuan, 1998, Seminars in Radiation Oncology, 8(3): 164-175.
✓	Yuan <i>et al.</i> , 1994, Cancer Research, 54: 3352-3356.
✓	Yuan <i>et al.</i> , 1995, Cancer Research, 55: 3752-3756.

Examiner: _____	Date Considered: _____
-----------------	------------------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED
MAY 13 2002
TECH CENTER 1600/2900